New York, United States
Intelligencia AI, founded in 2017, is a United States-based company specializing in applying machine learning to the drug development process. Their platform aims to de-risk clinical trials by evaluating and interpreting complex factors influencing trial outcomes, ultimately expediting the delivery of novel therapies to patients. The company's slogan, "Applying machine learning in drug development," encapsulates their mission.
By integrating expertise from an interdisciplinary team comprising software engineers, AI experts, scientists, and drug developers, Intelligencia AI offers a data-driven platform that delivers transparency and facilitates informed decision-making for pharmaceutical and biotechnology firms. They serve a diverse clientele that includes some of the world's largest pharmaceutical companies and smaller biotech enterprises.
The company secured a Series A investment of $12.00M on August 10, 2021, with backing from investors such as Big Pi Ventures, MTIP, Synetro Ventures, and ZS Associates. This support underscores the confidence in their potential to revolutionize the pharmaceutical industry.
